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Capsule summary: 31 
In this study, Vitamin D supplementation results in improved clinical severity of 32 
atopic dermatitis and increased skin surface LL-37 levels, analyzed by a novel, non-33 
invasive method. Vitamin D supplementation could be a therapeutic option in AD. 34 
  35 
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To the Editor: 36 
Atopic dermatitis (AD) is a relapsing condition prone to infections such as Herpes 37 
Simplex virus (HSV), resulting in AD with Eczema Herpeticum (ADEH), (a more 38 
severe clinical manifestation).1 Recent medical research has implicated Vitamin D 39 
(VD) in AD. 2, 3 It appears essential for skin barrier structure, increasing pro-filaggrin 40 
and lipid lamella production.4 Of interest is the effect of VD on the antimicrobial 41 
peptide LL-37 expression,3 which demonstrates significant anti-viral activity against 42 
HSV, and immune modifying characteristics. 5  43 
Modern research has demonstrated low LL-37 levels in AD and ADEH patients,6 44 
increasing after VD supplementation.3, 7 VD deficiency has been inversely correlated 45 
with AD severity.8 Furthermore, a few randomized controlled trials found AD 46 
improvement with VD supplementation.7, 9-12 Despite these major advances, the extent 47 
of VD deficiency in AD is unknown.  48 
We conducted a clinical service evaluation at the Sheffield Children’s Hospital 49 
Dermatology Department to firstly determine the level of VD deficiency in AD 50 
children and establish its association with disease severity. Secondly we aimed to 51 
establish the effect of VD supplementation on AD, using LL-37 levels as a prognostic 52 
marker.  53 
Following approval by the Sheffield Children’s Hospital (CA309), AD children were 54 
screened for VD deficiency during three summer months. 25 (OH) VD levels were 55 
classified as: >75 nmol/L = sufficient, < 75 = insufficient (50-75 nmol/L = 56 
suboptimal, <50 nmol/L = deficient).13 AD children with insufficient 25(OH) VD 57 
levels were then assessed clinically on a subsequent visit using SCORAD by a single 58 
dermatologist. POEM scores were also determined. LL-37 levels were quantified 59 
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 5 
from superficial samples of stratum corneum using novel method described in the 60 
supplementary material. This group was supplemented for two months depending 61 
upon the level of deficiency and age (cholecalciferol 6000 IU daily in ages 1-12 years; 62 
10,000 IU daily for ages 12-18) for 2 months, as recommended by the British 63 
National Formulary. Sub-optimal levels were corrected with over-the-counter (OTC) 64 
preparations containing 100% RDA of VD. On the third visit all levels were re-65 
checked and clinical severity reassessed. Patients continued all other topical and oral 66 
medications. If in need of new oral treatment, the patient was not included in the final 67 
analysis.  68 
Ninety children between the ages of 1 and 18 (mean age 9) attended the dermatology 69 
clinic during the period of this clinical audit and underwent screening for VD 70 
(Demographics in supplement, TableS1). The majority of patients were receiving 71 
topical immunotherapy; eleven were on oral immuno-suppressants for more than one 72 
year prior to the study. Baseline 25(OH)VD levels revealed 57 % patients with VD 73 
deficiency, and a further 26% with sub-optimal levels, totaling 83% with insufficient 74 
VD levels. 75 
ADEH patients comprised 51% of the sample population. Baseline 25(OH) VD levels 76 
were significantly lower in ADEH (37± 20 nmol/l) than AD patients (61± 28 77 
nmol/l, p <0.001, two sample t test, Figure 1A). Only two ADEH patients had normal 78 
25(OH) VD levels. 79 
After screening, 18 patients were lost to follow up (Figure S1); 10 patients excluded 80 
due to commencement of oral therapy. Consequently, a total of 47 patients were 81 
analyzed: 12 AD and 35 ADEH. Patients with normal VD levels were not followed up 82 
as part of this audit. 83 
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Using SCORAD, patients were classified into: mild <25, moderate 25-50 and severe 84 
>50,8  and showed a significant difference in 25(OH)VD levels (Figure 1B, means 85 
31±17, 40±15, and 57±21 respectively, p = 0.02, one way ANOVA). Bonferonni’s 86 
post-test showed a significant difference between mild and severe scores (p = 0.01). A 87 
significant inverse relationship was found between 25(OH) VD and SCORAD (p = 88 
0.01, Pearson’s r = - 0.36). LL-37 levels were also significantly different between the 89 
groups; with the most severe AD patients displaying the lowest levels (Figure 1C, p 90 
=0.018, one way ANOVA). Bonferroni’s post-test revealed a significant relationship 91 
between both mild and moderate (p =0.04), and mild and severe groups (p= 0.01). 92 
ADEH children had lower LL-37 than AD children (n=35, mean score 0.4 ±0.5 g/g; 93 
n=12, mean score 0.5 ±0.6 g/g respectively; p=0.46). Moreover 25(OH) VD levels 94 
were found to correlate with LL-37 levels (Figure 1D, r =0.3, p=0.02).  95 
Following a 2-month period of VD supplementation SCORAD and POEM improved 96 
significantly with a mean reduction of 42% and 47% respectively (p < 0.001, Figure 97 
2a and b, paired t test). This improvement in severity was accompanied by a 98 
significant increase in LL-37 levels (lesional and non-lesional) by 4-fold (therapeutic 99 
or OTC) (p = 0.0004, Figure 2c, d and e, two sample t test). The severity of AD was 100 
significantly correlated with LL-37 (r= -0.32, p =0.01), suggesting a causal 101 
relationship. 102 
VD deficiency is now recognized as a worldwide problem. Recently 35-40 % of 103 
healthy UK 14 and US children 15 were VD deficient. A study in Kuwait showed 57% 104 
of AD children with less than 50nmol/l.16 Our study shows VD levels significantly 105 
lower in children with moderate and severe AD compared to mild AD, similar to 106 
recent studies.8 Children with ADEH also displayed significantly lower VD levels 107 
than those with AD.  108 
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LL-37 levels are up-regulated in wound injury to participate in re-epithelialization.4 109 
Previous studies have reported low LL-37 levels in AD3, with further reductions in 110 
ADEH.6, 17 This was echoed here, but not statistically significant, possibly due to the 111 
smaller sample size of AD patients (AD =12 vs. ADEH= 35). 112 
VD supplementation has previously been shown to increase lesional and non-lesional 113 
LL-37 levels in skin biopsies of AD patients.2, 3 Moreover RCTs have reported 114 
reduced AD severity with VD supplementation.7, 9-12 In our study, two months VD 115 
supplementation significantly improved AD and ADEH severity; LL-37 levels also 116 
increased significantly within the stratum corneum. Therefore VD deficiency could 117 
lead to a decrease in LL-37, resulting in reduced antimicrobial defense and increased 118 
disease severity with secondary infections.  119 
As VD itself has been reported to influence lipid lamellae formation,4 it could have 120 
contributed to improved AD in our cohort by improving permeability barrier function. 121 
The discovery of increased VDR polymorphisms in AD patients in comparison to 122 
healthy controls, suggests an important role of VD in the pathogenesis of AD.18  123 
This was a practice evaluation study designed to emulate regular clinical practice not 124 
a randomized controlled trial. All medications continued with no constraints. Another 125 
limitation of this study is the lack of clinical scores in the AD patients with normal 126 
25(OH) VD levels, to allow for unknown factors that could contribute to clinical 127 
improvement. In addition, our study could be underpowered to detect differences due 128 
to the sample size.  Nevertheless, the significant results of VD supplementation in this 129 
study, renders that possibility unlikely.  130 
In conclusion, VD deficiency is common, and could lead to decreased LL-37 levels 131 
and increased severity of AD and ADEH. We developed a novel, non-invasive 132 
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 8 
method for quantifying LL-37 that simplifies collection, permitting analysis of larger 133 
and younger populations. Monitoring of this peptide may be a useful prognostic 134 
clinical marker. Further research and larger samples are necessary to fully examine 135 
the relationship between VD and LL-37.  136 
 137 
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Figure Legends: 172 
Figure 1:  Pre supplementation analysis. (A) Baseline VD level comparison. ADEH 173 
children (black dots, n=45) with lower VD levels than AD (gray squares, n=45). 174 
Levels 50-75 nmol/l (dotted lines) = suboptimal, < 50 nmol/l = deficient. (B) AD 175 
patients (47) classified into: severe AD (n=13), moderate AD (n= 30), and mild AD 176 
(n=4) showed significantly different VD levels (C) Baseline LL-37 levels stratified 177 
according to SCORAD were significantly different  (D) VD and LL-37 correlation (p 178 
= 0.01). 179 
Figure 2: Post-supplementation analysis (n=47). (A) SCORAD reduced 42.3% post-180 
supplementation. (B) POEM showed significant reduction (46.6%). (C) LL-37 levels 181 
increased significantly from mean = 2 ± 0.7 Log10 (LL-37pg/g) to 2.8 ± 0.8 182 
Log10(LL-37pg/g). (D) Lesional LL-37 increased from mean = 2.3± 0.7 Log10LL-183 
37pg/g to mean= 3 ± 0.7 Log10(LL-37pg/g). (E) Non lesional LL-37 increased from 184 
mean = 2.3 ± 0.6 Log10(LL-37pg/g) to 2.7 ± 0.8 Log10(LL-37pg/g).  185 
 186 
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Demographics of the AD children 
Characteristics Initial AD children 
screened (n=90)  
AD children included in 
study (n=47)  
 
Age mean age=9 (1-18) Mean age=11(1-18) 
 
Gender:  
Females 
males 
 
47 (52%) 
43 (48%) 
 
21 (45%) 
26 (55%) 
 
Ethnicity:  
Caucasian 
Asian 
Chinese 
African 
mixed 
 
57(63%) 
24 (27%) 
3 (4%) 
2 (2%) 
4 (4%) 
 
25 (53%) 
14 (30%) 
3 (6%) 
1 (2%) 
4 (9%) 
 
Clinical classification: 
AD 
ADEH 
 
45 (50%) 
45 (50%) 
 
12 (26%) 
35 (74%) 
 
Healthy 25(OH)VD levels 
Unhealthy 25(OH)VD levels: 
- Sub optimal 25(OH)VD 
(50-75nmol/l) 
- Deficient 25(OH) VD 
(<50nmol/l) 
- Severely deficient VD 
(<25nmol/l) 
15 (17 %) 
75 (83%) 
 
23 (26 %) 
 
35 (39%) 
17 (18%) 
 
47 
12 (25%) 
 
23 (50%) 
 
12 (25%) 
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Supplementary Information 1 
Materials and Methods 2 
Sample collection and quantification of LL-37 3 
Skin cells were collected using non-invasive cytology brushes (Cytotak brushes, Medical Wire 4 
Co., UK) from lesional and non-lesional sites of the VD deficient patients. Three brushes were 5 
gently brushed against the skin surface, placed in 1.5 ml tube, and frozen at – 80°C. The samples 6 
were extracted in 800µl buffer (10 mM disodium phosphate pH 7.4, 0.2% sodium dodecyl 7 
sulphate, 0.5% propylene glycol) containing protease inhibitors (Complete mini, Roche, 8 
Germany) for 30 minutes with sonication (Ultrawave Ltd. UK). The LL-37 levels were 9 
determined using the Human LL-37 ELISA kit (Hycult, The Netherlands), and expressed as a 10 
proportion of total protein, determined by Bicinchoninic Acid (BCA) analysis (Sigma-Aldrich, 11 
UK).  12 
Statistical Analysis 13 
GraphPad Prism (UK) was used for statistical analysis. AD and ADEH groups were analyzed by 14 
two sided two-sample t-test. Scatter plot of AD vs ADEH shows mean and standard deviation 15 
(SD). One-way analysis of variance (ANOVA) was used to compare VD levels and LL-37 levels 16 
stratified by clinical severity. Post-hoc comparisons were analyzed with Bonferroni’s multiple 17 
comparisons test. Boxplot graphs show midline to represent median; boxes represent the 25th and 18 
75th quartile, and whiskers represent the minimum to maximum values.  Pearson's analysis was 19 
used for correlations between LL-37, VD levels, and SCORAD. SCORAD and POEM 20 
measurements collected before and after VD supplementation were analyzed by paired t-test. 21 
LL37 levels collected before and after were analyzed by two-sample t test. Level of significance 22 
was set at 0.05. All values were expressed as mean ± standard deviation. 23 
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TableS1: Demographics of sample population. n=90 the total amount of children screened 24 
initially. n=47 the amount of children entered into the practice evaluation study, supplemented 25 
and clinically evaluated. 26 
Figure S1: Flowchart of study. 90 AD children screened for VD deficiency and classified into 27 
AD and ADEH groups on initial consultation. Of these 90, 15 were found to have normal VD 28 
levels, 75 had low VD levels. Of the 75 AD children, 18 lost to follow up and 10 excluded. 29 
Therefore 47 children were included in the practice evaluation study. These 47 children were 30 
clinically assessed and supplemented. 31 
Figure S2: IgE level did not show significant change from mean score 7010 ± 2370 nmol/l to 32 
7824 ± 3221nmol/l (p =0.93, unpaired t-test). 33 
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